Diabetes mellitus is one of the best quantified human conditions: elaborate models describe the action of the metabolic system, real-time signals, such as continuous glucose monitoring (CGM), are readily available, insulin delivery can be automated, and advancing artificial pancreas (AP) technology is increasingly capable of controlling blood glucose fluctuations in a patient's natural environment. This evidence concerns the gene INS and diabetes mellitus.